Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.32 USD | -0.16% | -.--% | +14.29% |
05-08 | Crescita Therapeutics Q1 Loss Widens, Revenue Rises | MT |
05-08 | Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 9.352 | 19.29 | 14.45 | 13.64 | 13.49 | 9.795 |
Enterprise Value (EV) 1 | 5.121 | 11.51 | 1.342 | 5.097 | 6.795 | 1.661 |
P/E ratio | 3.66 x | 10.8 x | 397 x | -12.2 x | 16.5 x | -4.9 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.56 x | 0.86 x | 0.92 x | 0.81 x | 0.57 x | 0.56 x |
EV / Revenue | 0.31 x | 0.52 x | 0.09 x | 0.3 x | 0.29 x | 0.09 x |
EV / EBITDA | 4.62 x | 1.8 x | 0.66 x | -10.6 x | 4.21 x | -1.94 x |
EV / FCF | -1.94 x | 1.97 x | 0.35 x | -2.23 x | -4.36 x | 0.81 x |
FCF Yield | -51.5% | 50.7% | 285% | -44.9% | -22.9% | 124% |
Price to Book | 0.49 x | 0.91 x | 0.68 x | 0.66 x | 0.64 x | 0.52 x |
Nbr of stocks (in thousands) | 21,016 | 20,742 | 20,648 | 20,983 | 20,442 | 19,989 |
Reference price 2 | 0.4450 | 0.9300 | 0.7000 | 0.6500 | 0.6600 | 0.4900 |
Announcement Date | 21/03/19 | 18/03/20 | 24/03/21 | 23/03/22 | 15/03/23 | 13/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 16.63 | 22.34 | 15.64 | 16.77 | 23.52 | 17.52 |
EBITDA 1 | 1.109 | 6.393 | 2.019 | -0.479 | 1.613 | -0.857 |
EBIT 1 | -0.037 | 4.968 | 0.833 | -1.496 | 0.529 | -1.956 |
Operating Margin | -0.22% | 22.24% | 5.33% | -8.92% | 2.25% | -11.16% |
Earnings before Tax (EBT) 1 | 0.649 | 3.18 | 0.52 | -1.009 | 0.404 | -1.53 |
Net income 1 | 2.396 | 1.855 | 0.037 | -1.105 | 0.862 | -1.986 |
Net margin | 14.41% | 8.3% | 0.24% | -6.59% | 3.66% | -11.33% |
EPS 2 | 0.1216 | 0.0865 | 0.001764 | -0.0532 | 0.0400 | -0.1000 |
Free Cash Flow 1 | -2.635 | 5.838 | 3.822 | -2.286 | -1.559 | 2.059 |
FCF margin | -15.85% | 26.13% | 24.44% | -13.64% | -6.63% | 11.75% |
FCF Conversion (EBITDA) | - | 91.31% | 189.31% | - | - | - |
FCF Conversion (Net income) | - | 314.7% | 10,330.07% | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 21/03/19 | 18/03/20 | 24/03/21 | 23/03/22 | 15/03/23 | 13/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 4.23 | 7.78 | 13.1 | 8.54 | 6.7 | 8.13 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -2.64 | 5.84 | 3.82 | -2.29 | -1.56 | 2.06 |
ROE (net income / shareholders' equity) | 15.1% | 9.25% | 0.18% | -5.3% | 4.14% | -9.95% |
ROA (Net income/ Total Assets) | -0.09% | 11.4% | 1.94% | -3.35% | 1.15% | -4.61% |
Assets 1 | -2,599 | 16.25 | 1.907 | 32.95 | 74.84 | 43.12 |
Book Value Per Share 2 | 0.9000 | 1.020 | 1.020 | 0.9800 | 1.040 | 0.9400 |
Cash Flow per Share 2 | 0.4100 | 0.4500 | 0.6900 | 0.5400 | 0.4100 | 0.4700 |
Capex 1 | 0.14 | 0.22 | 0.06 | 0.35 | 0.23 | 0.13 |
Capex / Sales | 0.87% | 0.96% | 0.38% | 2.06% | 0.97% | 0.76% |
Announcement Date | 21/03/19 | 18/03/20 | 24/03/21 | 23/03/22 | 15/03/23 | 13/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+28.95% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+17.03% | 240B | |
+9.08% | 208B | |
-7.81% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- CTX Stock
- CRRTF Stock
- Financials Crescita Therapeutics Inc.